Ebba Sjögren
Ebba Sjögren
Associate Professor, Stockholm School of Economics and Stockholm Business School
Verifierad e-postadress på hhs.se
Titel
Citeras av
Citeras av
År
Valuation studies? Our collective two cents
H Kjellberg, A Mallard, DL Arjaliès, P Aspers, S Beljean, A Bidet, A Corsin, ...
Valuation Studies 1 (1), 11, 2013
1372013
The Q (u) ALYfying hand: Health economics and medicine in the shaping of Swedish markets for subsidized pharmaceuticals
E Sjögren, CF Helgesson
The Sociological Review 55 (2_suppl), 215-240, 2007
842007
Valuation studies and the critique of valuation
L Doganova, M Giraudeau, CF Helgesson, H Kjellberg, F Lee, A Mallard, ...
Valuation Studies 2 (2), 87-96, 2014
482014
Reasonable drugs: Making decisions with ambiguous knowledge
E Sjögren
Economic Research Institute, Stockholm School of Economics (EFI)., 2006
372006
Valuation and Calculation at the Margins
A Mennicken, E Sjögren
Valuation Studies 3 (1), 1-7, 2015
312015
‘Accounting Talk’ Through Metaphorical Representations: Change Agents and Organisational Change in Home-Based Elderly Care
M Carlsson-Wall, K Kraus, M Lund, E Sjögren
European Accounting Review 25 (2), 215-243, 2016
262016
Glocal Pharma
E Johnson, E Sjögren, C Åsberg
Taylor & Francis, 2016
152016
More Knowledge, Better Government? Consequences of Knowledge‐Based Decision Making in Swedish Pharmaceutical Benefits
ÅC Vifell, E Sjögren
Governance 24 (1), 85-110, 2011
152011
Identifying need through expressions of demand: Deciding on public financial intervention within the fields of healthcare and development aid
A Krohwinkel-Karlsson, E Sjögren
Routledge 10 (2), 197-220, 2008
112008
The legal mind of the internal market: A governmentality perspective on the judicialization of monitoring practices
ÅC Vifell, E Sjögren
JCMS: Journal of Common Market Studies 52 (3), 461-478, 2014
102014
Deciding subsidy for pharmaceuticals based on ambiguous evidence
E Sjögren
Journal of Health, Organisation and Management 22 (4), 368-383, 2008
92008
Decision usefulness explored: An investigation of capital market actors' use of financial reports
A Hjelstrom, T Hjelstrom, E Sjogren
Stockholm, Svenskt Naringsliv, 2014
72014
Defining ‘markets’ for pharmaceuticals in Sweden: Public policy and commercialization
E Sjogren
Minerva 45 (2), 161-173, 2007
72007
No finish line: How formalization of academic assessment can undermine clarity and increase secrecy
KS Helgesson, E Sjögren
Gender, Work and Organization 26 (4), 558-581, 2019
52019
Democratic priority-setting? Organizing multiple stakeholders to make decisions in the healthcare sector
E Sjögren, K Fernler
L. Sonderyd, G. Sundström and S. Furusten, Organizing Democracy: The …, 2010
52010
Reasonable drugs
E Sjögren
Making Decisions with Ambiguous Knowledge, 2006
52006
Role attribution in public sector accountability processes: Dynamic and situation-specific accountor and constituent roles
E Hagbjer, K Kraus, J Lind, E Sjögren
Qualitative Research in Accounting & Management, 2017
42017
Trust in the Monitoring of Publicly Funded Services: A Case Study of Two Outsourced Care Homes for the Elderly
E Hagbjer, J Lind, E Sjögren
Trust and Organizations, 147-164, 2013
42013
Prescribing for the “Swedish Viagra Man”
E Johnson, E Sjögren, C Åsberg
Clinical pharmacology and therapeutics 89 (1), 15, 2011
42011
Five years! Have we not had enough of valuation studies by now?
L Doganova, M Giraudeau, H Kjellberg, CF Helgesson, F Lee, A Mallard, ...
Valuation Studies 5 (2), 83-91, 2018
32018
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20